Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET

September 13, 2023

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET

September 7, 2023

IMUNON to Participate in the H.C. Wainwright Global Investment Conference

September 5, 2023

Financial Events

H.C. Wainwright 25th Annual Global Investment Conference

September 11, 2023

Imunon’s Second Quarter 2023 Financial Results

August 10, 2023 at 11:00 AM EDT